Lancet publishes randomised trial of weekly semaglutide in alcohol use disorder
The double-blind, placebo-controlled study enrolled patients with alcohol use disorder and comorbid obesity, a population where incretin effects on drinking have been debated.
PR
By Priya Raman · Science Reporter
May 2 03:00 ETSource: The Lancet
The wire
- 01The Lancet reports a randomised, double-blind, placebo-controlled trial of once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity.
- 02Off-label interest in GLP-1s for addiction has run ahead of controlled data, so a randomised readout gives clinicians something firmer to cite.
- 03Results should be read against the enrolled population, which had comorbid obesity, limiting generalisation to patients with alcohol use disorder alone.
From the source
Read at thelancet.comOnce-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial